The Dementia Claim That Prints Its Own Rebuttal

Why does FDA name Alzheimer's and senile dementia by name?

FDA names Alzheimer's disease and senile dementia directly, in its own final-rule text, as conditions that remain disease claims — FDA's drug-triggering label category — no matter how a supplement page frames the promise. The 2000 structure/function preamble puts Alzheimer's beside glaucoma as conditions the agency will not let ordinary supplement claims reach, in contrast to presbyopia, which it treats as fair game, and adds that '[u]ncommon or serious conditions like senile dementia... will continue to be treated as diseases under the final rule,' per FDA's preamble.

No verb, no promise, no 'may' saves it once the word appears.

Compare the door FDA left open elsewhere in supplement copy. Occasional symptoms get an escape hatch — occasional constipation is allowed with a specific condition attached — because 'occasional' signals a common, self-limiting state rather than a disease. Dementia gets no equivalent hatch: the test at 21 CFR 101.93(g)(2)(iii) asks whether a condition is uncommon or can cause significant or permanent harm, and FDA's own naming puts dementia on the wrong side of both, explicitly, not by inference.

The line FDA does draw is age-related forgetfulness, not disease. The same preamble protects 'mild memory problems associated with aging' as available claim territory, and treats plain absentmindedness as too mild to imply Alzheimer's — a distinction that matters because it's the only cognitive claim ground this niche gets without a qualified health claim attached to it.

What is the only claim FDA extends enforcement discretion to here?

The one legal opening is the phosphatidylserine qualified health claim — a claim carrying FDA's own doubt — granted by enforcement discretion, FDA choosing not to act, on May 13, 2003 under Docket 2002P-0413. FDA authorized exactly two versions: one naming dementia in the elderly, one naming cognitive dysfunction in the elderly. Neither is a structure/function claim, DSHEA's non-disease label route; both run under the health-claim track at 21 CFR 101.14, which is why the ordinary DSHEA disclaimer covering everyday supplement copy does not apply to this claim at all.

There is no third option.

Set this against a niche with real headroom. FDA authorized twelve health claims total, and one of them covers a related organ system — urinary health carries an authorized claim that kidney health never got — which is still more room than cognition gets anywhere. Dementia has one discretionary letter, for one ingredient, at a purity threshold FDA never pinned to a specific dose.

What disclaimer has to run with it, and in what format?

The disclaimer has to sit immediately adjacent to and directly beneath the claim, in the same size, typeface and contrast as the claim itself — not a footnote, not a linked asterisk, not a separate screen a reader has to tap through. FDA's 2003 letter states the condition as one sentence: the disclaimer must sit immediately adjacent to and directly beneath the claim, with no intervening material, in the same size, typeface and contrast as the claim itself.

• Claim text comes in two authorized versions, for 'dementia in the elderly' or 'cognitive dysfunction in the elderly,' each naming phosphatidylserine specifically.
• Disclaimer prints FDA's own verdict inside the ad: 'FDA concludes that there is little scientific evidence supporting this claim.'
• Placement: adjacent to and directly beneath the claim, matching size, typeface and contrast, with no intervening material.
• Purity condition: if the source is synthetic phosphatidylserine (S-PS), it has to be of very high purity.

Why does that formatting rule make the claim unusable in most ad units?

Most ad formats don't have room for a disclaimer sized to match the claim and sitting directly beneath it, so the format kills the claim before FDA ever reviews the copy. A Meta feed unit, a search headline, a TikTok caption — none of them give you space for a sentence, at claim-size type, admitting the evidence is little.

Even where the space exists — a long-form advertorial, a full landing page — the claim still has to survive a second, independent regime layered on top. FTC's own compliance guidance treats a banner reading that a product 'meets FDA's qualified health claim' as deceptive on its own, and FTC still demands the same randomized, controlled human clinical trial standard it applies to every other supplement claim, which means the qualified claim buys you cover with FDA and buys you nothing with FTC. An advertiser who prints the disclaimer correctly, in the right size, directly beneath the right claim, has satisfied one agency and done nothing for the other. That gap is what makes this claim close to worthless in a performance-media context, whatever the underlying labeling regulation was written to accomplish.

What did FDA itself conclude about the underlying evidence?

FDA concluded the evidence itself is thin, in its own words — 'FDA concludes that there is little scientific evidence supporting this claim' isn't marketing hedge language, it's the agency's finding, baked permanently into the disclaimer advertisers are required to run.

We found the 2004 correction letter more consequential than most compliance write-ups treat it. FDA's original 2003 reasoning leaned on a very small number of outcome measures out of the large number measured across five trials; a 2004 update admitted FDA had wrongly assumed those trials studied sick populations, and redid the analysis on four trials, three of which supported the relationship. The conclusion held anyway — very limited and preliminary, short of significant scientific agreement — and the claim wording never changed.

Why can't a rewrite cure the 'adequate directions for use' theory?

A rewrite can't cure it because the charge isn't about wording — it's misbranding, unlawful labeling under the FD&C Act, built on whether ordinary directions can exist at all for a condition that requires a doctor to diagnose. FDA's Jan. 23, 2026 letter to Intelligent Remedies, Inc. applied exactly this reasoning to six of the company's nine products, finding them intended for diseases 'not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson.'

Softer language doesn't change who can diagnose Alzheimer's.

Removing the disease claim removes both charges, FDA notes, because the misbranding charge flows from the intended use the disease claim creates — but that only works if the change happens in what the product is actually offered to treat, not just in the ad copy sitting on top of it. The same logic reaches your back end: how you word a money-back guarantee is itself a claim, separate from whatever the front-end copy promises.

How does an audience list like 'Alzheimer's patients' become the claim?

Naming who the product is for functions as a disease claim in FDA's reading, through the intended use doctrine, FDA's test for real purpose, and the catch-all at 21 CFR 101.93(g)(2)(x) sweeps in anything that suggests a disease effect. FDA's July 29, 2025 letter to AlzClipp / UniUni listed an audience block naming Alzheimer's disease patients, individuals diagnosed with dementia and patients clinically diagnosed with memory decline among the evidence establishing drug intended use, next to express efficacy lines promising to reverse dementia and prevent Alzheimer's disease outright.

A quiz funnel that sorts users into 'likely dementia' is doing the same thing.

FDA hasn't ruled on audience descriptors standing alone, so treat quiz results, 'is this you?' landers and audience-definition blocks as claim risk rather than a safe harbor. We could not confirm whether Meta's enumerated list of incurable conditions — diabetes, cancer, autism, HIV — is exhaustive or merely illustrative, because the policy page renders client-side and returned no text on direct fetch; reading it live in a browser is what would settle that before you rely on Alzheimer's sitting outside Meta's named list.

Does the FTC losing the Neora case change the risk math?

Losing does happen, and Neora is the proof — but one loss on the merits after a five-year defense doesn't move the odds in an advertiser's favor. FTC sued Neora, formerly Nerium International, alleging its 'EHT' supplement was promoted as an antidote to concussions and chronic traumatic encephalopathy from repetitive brain trauma, and separately to Alzheimer's disease and Parkinson's disease.

In September 2023, per FTC's own case page, 'the district court ruled against the FTC on its claims,' and in May 2024 the court held Neora could not recover its legal fees because FTC's position had been substantially justified rather than baseless. The case is closed now. The defense, though, ran from 2019 to 2024 — five years of litigation an advertiser has to fund regardless of the eventual verdict.

We read Neora as the exception that proves the pattern rather than a reason to relax it. FTC still won Prevagen, still settled Lumosity within days of filing, and is still litigating Amare Global Holdings on the same cortisol-and-neurotransmitter narrative this record shows repeating across cognitive niches — Alzheimer's included, since caregivers, not patients, are disproportionately the ones reading the ad.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Herbal Prozac, Nature's Adderall: Substitute Claims, Why 'Results Not Typical' Stopped Protecting Ads, Your Money-Back Guarantee Wording Is a Claim, Anti-Aging's Floor: Alzheimer's, Osteoporosis, Glaucoma, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.